Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.

The entities involved

• Amgen →

  American multinational biopharmaceutical company

  • Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
  • Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
• BioCryst Pharmaceuticals →

  American pharmaceutical company

  • ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.Wed 11:22
• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52

Related events

• GSK and Amgen are major biopharma players.Sep 8
• Joint drug trial success boosts Amgen stock.Sep 9
• Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.Tue 21:48
• Amgen Inc. trades on the NASDAQ stock exchange.Jun 7
• Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Jun 7